Metformin Extended Release Treatment of Adolescent Obesity

Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study

“…When the BMI change during the control period was examined separately for those starting on exenatide vs. control, there was some suggestion of a possible order effect (i.e., greater increase in BMI during the post-exenatide control period), although not statistically significant. Nevertheless, these results are in line with the previous studies of orlistat and metformin, which reported weight-gain in the placebo groups (17;18). In contrast, when exenatide therapy was provided, participants not only stopped their BMI gain, but reduced their BMI by 0.90 kg/m 2 .…”

Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study

“…However, our results failed to show an effect of metformin on insulin sensitivity. Similar results were obtained by others [28, 37]. The failure of metformin to significantly affect insulin sensitivity could be due to the low insulin-resistant status of our participants, as our children had relatively lower insulin levels than those published in other studies.…”

Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study

“…The high dropout is in concordance with other obesity studies, irrespectively of study duration 15 , 19 , 21 , 23 , 24 , and also observed during routine clinical care at pediatric (obesity) outpatient clinics. Since studies in populations with obesity are limited by the number of inclusions and high dropouts, it is suggested that for RCT’s less restrictive inclusion/exclusion criteria should be used in combination with the formation of research networks to accomplish adequate inclusion numbers 42 .…”

“…The difference between the MM subgroup and the others could not be fully elucidated; however, the sharp increase in HOMA-IR might possibly be the first sign towards development of T2DM. Metformin seems not to have major effects on HOMA-IR, although the PM subgroup decreased slightly more than the MP and PP subgroup, which is in line with literature 16 , 17 , 21 , 22 . Since IR is known to be associated with BMI, the increasing BMI in some participants might possibly have influenced the results 5 , 30 .…”